Robert Piskol Selected Research

Neoplasms (Cancer)

1/2023	T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interaction.
1/2022	CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
1/2022	Identifying transcriptional programs underlying cancer drug response with TraCe-seq.
1/2022	Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
1/2021	Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.
11/2020	Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
1/2020	MAP4K4 negatively regulates CD8 T cell-mediated antitumor and antiviral immunity.
1/2020	Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
1/2020	Colon Cancer Heterogeneity: Welcome to the RiboZone.
1/2019	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Piskol Research Topics

Disease

12	Neoplasms (Cancer) 01/2023 - 11/2010
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2017
2	Breast Neoplasms (Breast Cancer) 11/2019 - 01/2018
1	Hypothyroidism 12/2023
1	Microsatellite Instability 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Melanoma (Melanoma, Malignant) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Bites and Stings (Sting) 01/2020
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Cytokine Release Syndrome 01/2019
1	Residual Neoplasm 10/2018
1	Disease Progression 01/2017

Drug/Important Bio-Agent (IBA)

3	Phosphotransferases (Kinase)IBA 01/2022 - 01/2021
2	AntigensIBA 01/2022 - 01/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2021
2	CytokinesIBA 01/2020 - 01/2019
2	Glial Cell Line-Derived Neurotrophic Factor ReceptorsIBA 11/2019 - 01/2018
2	Hormones (Hormone)IBA 11/2019 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 11/2019 - 01/2018
1	Thyroid HormonesIBA 12/2023
1	Bispecific AntibodiesIBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Sucrose (Saccharose)IBA 11/2020
1	Interferon Type IIBA 01/2020
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2020
1	c-Mer Tyrosine KinaseIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 01/2020
1	ParaffinIBA 01/2019
1	Formaldehyde (Formol)FDA Link 01/2019
1	HhAntag691IBA 10/2018
1	Valine (L-Valine)FDA Link 01/2018
1	CitrullineIBA 01/2018
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	AntibodiesIBA 01/2018
1	Leucine (L-Leucine)FDA Link 01/2017
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 11/2010

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2019
2	Immunotherapy 01/2023 - 01/2020
1	Withholding Treatment 10/2018